PinPointe FootLaser has received approval for the treatment for toenail fungus (Onychomycosis) from from the Therapeutic Goods Administration (TGA). The approval certifies that it has met the TGA’s consumer and health safety standards. The device can be offered by certified health care providers throughout Australia and New Zealand. Introduced in 2008, the treatment has been awarded the CE Mark for use in the treatment of toenail fungus in the EU, and can be offered by healthcare providers throughout Europe. It is FDA cleared for applications in plastic surgery, dermatology and podiatry in the US.
John Strisower, CEO of PathoLase, noted: “Approximately 900 million people around the world suffer from toenail fungus, including millions in Australia and New Zealand. We’re very much looking forward to making PinPointe FootLaser available to practitioners in both countries, offering them an excellent opportunity for providing a unique and valuable service to their patients.”